Pegvisomant: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Pegvisomant. Educational only — not medical advice.

Labeled uses

SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels.

Source: FDA labeling via NIH DailyMed (set 3cbb485b…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.